Correction - Genflow Biosciences PLC Announces Issue of Equity
Genflow Biosciences (OTCQB:GENFF) has announced a significant equity issuance, raising £340,000 (before expenses) through the allotment of 40,000,000 new ordinary shares at 0.85 pence per share, representing a 35% discount to the October 1, 2025 bid price.
The transaction involves CEO Eric Leire subscribing to the shares under the employee offer exemption, who will then direct their issue to an institution for immediate sale to an identified purchaser. The purchaser will receive one-for-one warrants exercisable for 24 months at 1.2 pence. Upon admission, expected around October 9, 2025, the company's total issued shares will increase to 493,547,942.
Genflow Biosciences (OTCQB:GENFF) ha annunciato una significativa emissione di capitale, raccogliendo £340.000 (prima delle spese) mediante l’assegnazione di 40.000.000 nuove azioni ordinarie a 0,85 penne per azione, rappresentando uno sconto del 35% rispetto al prezzo di offerta del 1 ottobre 2025.
La transazione prevede che il CEO Eric Leire sottoscriva le azioni nell’ambito dell’esenzione di offerta ai dipendenti, che poi indirizzerà l’emissione a un istituto per la vendita immediata a un acquirente identificato. L’acquirente riceverà warrant 1:1 esercitabili per 24 mesi a 1,2 penne. Al momento dell’ammissione, prevista intorno al 9 ottobre 2025, il totale delle azioni emesse della società salirà a 493.547.942.
Genflow Biosciences (OTCQB:GENFF) ha anunciado una emisión de capital significativa, recaudando £340.000 (antes de gastos) mediante la asignación de 40.000.000 nuevas acciones ordinarias a 0,85 penique por acción, lo que supone un descuento del 35% respecto al precio de oferta del 1 de octubre de 2025.
La operación implica que el CEO Eric Leire suscriba las acciones bajo la exención de oferta para empleados, y que dirija su emisión a una institución para su venta inmediata a un comprador identificado. El comprador recibirá warrants 1 por 1 exercitables durante 24 meses a 1,2 penique. Tras la admisión, prevista alrededor del 9 de octubre de 2025, el total de acciones emitidas aumentará a 493.547.942.
Genflow Biosciences (OTCQB:GENFF)가 비용 차감 전 £340,000를 40,000,000주의 신규 보통주를 주당 0.85펜스에 배정하여 조달하는 중요한 자본 발행을 발표했습니다. 이는 2025년 10월 1일의 매수 가격 대비 35%의 할인에 해당합니다.
거래는 CEO Eric Leire가 직원 혜택 예외에 따라 주식을 구독하고, 이를 기관으로 이끌어 즉시 지정된 매수인에게 매각하도록 하는 구조입니다. 매수인은 24개월 동안 행사 가능한 1:1 워런트를 1.2펜스에 받게 됩니다. 상장 승인 예정일은 2025년 10월 9일경으로 예상되며, 발행 주식 총수는 493,547,942주로 증가합니다.
Genflow Biosciences (OTCQB : GENFF) a annoncé une émission d’actions importante, levant £340 000 (avant frais) grâce à l’attribution de 40 000 000 nouvelles actions ordinaires à 0,85 penny par action, soit une décote de 35% par rapport au prix d’offre du 1er octobre 2025.
La transaction prévoit que le PDG Eric Leire souscrive les actions dans le cadre de l’exemption d’offre employé, puis dirige leur émission vers une institution pour une vente immédiate à un acheteur identifié. L’acheteur recevra des warrants 1 pour 1 exerçables pendant 24 mois à 1,2 penny. À l’admission, prévue vers le 9 octobre 2025, le nombre total d’actions en circulation sera porté à 493 547 942.
Genflow Biosciences (OTCQB:GENFF) hat eine bedeutende Eigenkapitalmaßnahme angekündigt und rund £340.000 (vor Kosten) durch die Zuteilung von 40.000.000 neuen Stammaktien zu 0,85 Pence pro Aktie aufgenommen, was einem Rabatt von 35% zum Angebotspreis vom 1. Oktober 2025 entspricht.
Die Transaktion sieht vor, dass CEO Eric Leire die Aktien im Rahmen der Mitarbeiterangebot-Ausnahme zeichnet und diese Ausgabe dann an eine Institution weiterleitet, damit sie sofort an einen identifizierten Käufer verkauft werden kann. Der Käufer erhält 1:1-Warrants, die über 24 Monate zu 1,2 Pence ausübbar sind. Mit der Zulassung, voraussichtlich um den 9. Oktober 2025, wird die Gesamtzahl der ausgegebenen Aktien auf 493.547.942 erhöht.
أعلنت Genflow Biosciences (OTCQB:GENFF) عن إصدار أسهم مهم، حيث جُمِع £340,000 (قبل المصاريف) من خلال تخصيص 40,000,000 سهماً عادية جديدة بسعر 0.85 بنس للسهم، وهو يمثل خصماً بنسبة 35% عن سعر العرض في 1 أكتوبر 2025.
وتنص الصفقة على أن المؤسس والرئيس التنفيذي إيريك لير سيكتتب في الأسهم بموجب استثناء عرض الموظفين، ثم يوجه إصدارها إلى مؤسسة للبيع الفوري لمشتري محدد. سيحصل المشتري على أدوات warrants بسعر 1:1 قابلة للتنفيذ لمدة 24 شهراً بسعر 1.2 بنس. عند الإدراج، المتوقع حول 9 أكتوبر 2025، سيزداد إجمالي عدد الأسهم المصدرة إلى 493,547,942.
Genflow Biosciences (OTCQB:GENFF)宣布了一项重要的股本发行，通过配发40,000,000股新的普通股、价格为每股0.85便士，筹集金额为£340,000（费用前），较2025年10月1日的买入价有35%的折价。
该交易涉及首席执行官Eric Leire在员工优惠豁免下认购这些股份，随后将其发行转让给机构以便立即出售给指定的买家。该买家将获得1对1的认股权证，可在24个月内按1.2便士行权。预计于2025年10月9日左右上市时，公司总发行股数将增至493,547,942股。
- None.
- 35% discount to market price indicates challenging financing terms
- Significant dilution with 40 million new shares being issued
- Company unable to issue shares without prospectus, requiring employee offer exemption workaround
The following amendment has been made to the 'Subscription of New Ordinary Shares, Warrant Issue, PDMR Dealings' announcement released on 01 October 2025.
The sentence "being the bid price as at close of business on 1 October 2025" has been corrected to "being a
All other details remain unchanged.
The full amended text is shown below.
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
LONDON, UK, AL / ACCESS Newswire / October 2, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), is pleased to announce that it has raised gross proceeds of
Issuance of the New Ordinary Shares
The Company is currently unable to issue and admit the New Ordinary Shares without either the publication of a prospectus approved by the Financial Conduct Authority ("FCA") or relying upon an exemption to the requirement to issue a prospectus.
Consequentially, this fundraise involves a subscription by Eric Leire, CEO and director of the Company, for the New Ordinary Shares at the Issue Price pursuant to the employee offer exemption under Article 1(4)(i) and 1(5) (h) of the UK Prospectus Regulation.
Following allotment of the New Ordinary Shares, Eric Leire has agreed to direct their issue to an institution, who will immediately sell these New Ordinary Shares at the same Issue Price to a purchaser identified by it (the "Purchaser").
Warrants
Concurrent with the purchase of the New Ordinary Shares, the Purchaser will receive warrants from the Company on a one-for-one basis. These warrants will be exercisable for a period of 24 months at an exercise price of 1.2 pence ("Exercise Price").
Total Voting Rights
Application will be made for the 40,000,000 New Ordinary Shares, which will rank pari passu in all respects with the existing Ordinary Shares of the Company, to be admitted to the FCA official list and to trading on the equity shares (transition) category of the Official List maintained by the FCA and to trading on the main market for listed securities of the LSE, which is expected to occur on or around 8.00 a.m. on 9 October 2025 (the "Admission").
Upon Admission, the total number of issued shares and the total number of voting rights in the Company will be 493,547,942.
The above figure of 493,547,942 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Dr. Eric Leire, CEO of Genflow, commented: "We appreciate the continuing support from our US backer, and this will enable us to continue with dog study whilst awaiting the first payment of the Wallonia region grant. This financing provides Genflow with essential working capital while aligning long-term interests through the concurrent issue of warrants."
UK Market Abuse Regulation (UK MAR) Disclosure
Certain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement. The person responsible for arranging for the release of this announcement on behalf of Genflow Biosciences is Eric Leire, Chief Executive Officer.
Notification of transactions of directors, persons discharging managerial responsibilities or connected persons
1. | Details of the person discharging managerial responsibilities / person closely associated | ||
a) | Name | Eric Leire | |
2. | Reason for the Notification | ||
a) | Position/status | PDMR | |
b) | Initial notification / Amendment | Initial notification | |
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Genflow Biosciences plc | |
b) | LEI | 213800HVOFXRXVEGDN62 | |
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the Financial instrument, type of instrument | Ordinary Shares of | |
Identification Code | GB00BP2C3V08 | ||
b) | Nature of the transaction | Off Market Allotment | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
0.85 pence per Ordinary Share | 40,000,000 Ordinary Shares | ||
d) | Aggregated information: Aggregated volume Price | 40,000,000 Ordinary Shares 0.85 pence per Ordinary Share | |
e) | Dates of the transaction | 2 October 2025 | |
f) | Place of the transactions | London | |
Contacts
Genflow Biosciences | Harbor Access |
Dr Eric Leire, CEO | Jonathan Paterson, Investor Relations |
+32-477-495-881 | +1 475 477 9401 |
Jonathan.Paterson@Harbor-access.com |
About Genflow Biosciences
Founded in 2020, Genflow Biosciences Plc. (LSE:GENF)(OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned for 2025, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and X.
DISCLAIMER
The contents of this announcement have been prepared by, and are the sole responsibility of, the Company.
This announcement may contain forward-looking statements. The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words "anticipate", "believe", "continue", "could", "estimate", "expect", "intend", "may", "might", "plan", "possible", "potential", "predict", "project", "seek", "should", "would" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
Forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions.
Any forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company's actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and Transparency Rules of the FCA or the UK Market Abuse Regulation.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Genflow Biosciences PLC
View the original press release on ACCESS Newswire
FAQ
What is the size and price of GENFF's latest equity issuance?
How many warrants were issued in GENFF's October 2025 financing?
What will be GENFF's total shares outstanding after the new issuance?
How will Genflow Biosciences use the proceeds from the October 2025 equity raise?
What is the discount of GENFF's new share issuance compared to market price?
